Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,979 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Paz-Ares L, et al. Among authors: yoshida t. J Clin Oncol. 2023 Jun 1;41(16):2893-2903. doi: 10.1200/JCO.22.02823. Epub 2023 Jan 23. J Clin Oncol. 2023. PMID: 36689692 Free PMC article. Clinical Trial.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Goldman JW, et al. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. Lancet Oncol. 2021. PMID: 33285097 Clinical Trial.
Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis: a propensity-matched real-world analysis.
Tamura K, Okuma Y, Nomura S, Fukuda A, Masuda K, Matsumoto Y, Shinno Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Ohe Y. Tamura K, et al. Among authors: yoshida t. J Cancer Res Clin Oncol. 2024 Apr 26;150(4):216. doi: 10.1007/s00432-024-05649-x. J Cancer Res Clin Oncol. 2024. PMID: 38668936 Free PMC article.
Aldehyde dehydrogenase 1 expression in cancer cells could have prognostic value for patients with non-small cell lung cancer who are treated with neoadjuvant therapy: identification of prognostic microenvironmental factors after chemoradiation.
Zenke Y, Ishii G, Ohe Y, Kaseda K, Yoshida T, Matsumoto S, Umemura S, Yoh K, Niho S, Goto K, Ohmatsu H, Kuwata T, Nagai K, Ochiai A. Zenke Y, et al. Among authors: yoshida t. Pathol Int. 2013 Dec;63(12):599-606. doi: 10.1111/pin.12122. Pathol Int. 2013. PMID: 24422956
Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer.
Shibaki R, Murakami S, Shinno Y, Matsumoto Y, Yoshida T, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Yamamoto N, Ohe Y. Shibaki R, et al. Among authors: yoshida t. Cancer Immunol Immunother. 2020 Jul;69(7):1229-1236. doi: 10.1007/s00262-020-02539-2. Epub 2020 Mar 10. Cancer Immunol Immunother. 2020. PMID: 32152703 Free PMC article.
10,979 results
You have reached the last available page of results. Please see the User Guide for more information.